SEC Company Response from BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Jun 10, 2015
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: June 10, 2015 · CIK: 0001137883 · Accession: 0001144204-15-036388
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-204718
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Jeffrey P. Riedler Registration Statement on Form S-3 Filed June 4, 2015 File No. 333-204718 Acceleration Request
Dear Mr. Riedler:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Brainstorm Cell Therapeutics Inc. (the “Company”) hereby respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Wednesday, June 10, 2015, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
The Company acknowledges that:
● should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
● the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
● the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Any questions regarding this request should be addressed to Thomas B. Rosedale, Esq., at BRL Law Group LLC at (617) 399-6931.
Very truly yours,
Brainstorm Cell Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
BRAINSTORM CELL THERAPEUTICS INC.
3 University Plaza Drive, Suite 320
Hackensack, NJ 07601
June 10, 2015
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeffrey P. Riedler
RE:
Brainstorm Cell Therapeutics Inc.
Registration Statement on Form S-3
Filed June 4, 2015
File No. 333-204718
Acceleration Request
Dear Mr. Riedler:
Pursuant to Rule 461 of the Rules and Regulations
promulgated under the Securities Act of 1933, as amended, Brainstorm Cell Therapeutics Inc. (the “Company”) hereby
respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Wednesday,
June 10, 2015, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
The Company acknowledges that:
●
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
●
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
●
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Any questions regarding this request should
be addressed to Thomas B. Rosedale, Esq., at BRL Law Group LLC at (617) 399-6931.
Very truly yours,
Brainstorm Cell Therapeutics Inc.
/s/ Tony Fiorino, MD, PhD
By: Tony Fiorino, MD, PhD
Its: Chief Executive Officer
cc: Thomas B. Rosedale, Esq.
(BRL Law Group LLC)